YEDA RESEARCH AND DEVELOPMENT CO., LTD., v MYLAN PHARMACEUTICALS, INC., decided October 12, 2018, Prior Art

U.S. Patent Nos. 8,232,250, 8,399,413, and 8,969,302 are directed to higher dose (40mg v. 20mg) and less frequent injection (3 days a week v. daily) of a drug for multiple sclerosis (pages 3-4).  Prior art is 20 mg daily based on a clinical trial without an optimal dose finding study, but with a note to […]